Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022GlobeNewsWire • 09/21/22
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress SyndromeGlobeNewsWire • 09/19/22
Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress SyndromeGlobeNewsWire • 09/07/22
Veru to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12th, 2022GlobeNewsWire • 09/06/22
Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia's Therapeutic Goods AdministrationGlobeNewsWire • 08/22/22
Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 PatientsGlobeNewsWire • 08/19/22
Veru Inc. (VERU) CEO Mitchell Steiner on Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key TerritoriesGlobeNewsWire • 08/11/22
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August 7-1GlobeNewsWire • 08/09/22
Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11thGlobeNewsWire • 07/28/22
European Medicines Agency's Emergency Task Force Has Initiated the Review of Veru's Sabizabulin Treatment for Hospitalized COVID-19 Patients for Emergency Use in European Union CountriesGlobeNewsWire • 07/27/22
UK's Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 PatientsGlobeNewsWire • 07/25/22
Bear Market Winners: 3 Healthcare Stocks That Have Soared More Than 30% This YearThe Motley Fool • 07/14/22